Vixiar Medical, Inc., an Annapolis, MD-based company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, raised over $1.5m in seed financing.
Backers included the Abell Foundation, Maryland’s TEDCO and others from Asia, Europe and the US.
The company intends to use the proceeds to complete regulatory submissions and fund final engineering and initial production of its first product, Indicor™.
Led by Kevin Thibodeau, CEO, Vixiar develops non-invasive devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The company’s first product, Indicor™, is a handheld point of care device and digital platform for monitoring worsening heart failure. Vixiar is a spinout of Johns Hopkins.
FinSMEs
24/07/2017